NCT03185208CompletedPhase 4
Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia
Source: ClinicalTrials.gov · Last updated 11 Sept 2025
Brief summary (registry, in English)
Alzheimer's disease (AD) is the most common cause of dementia in adults 65 years and older. AD leads to a complete loss of memory and independent function, and presently there is no cure. Many studies suggest that lithium treatment may delay dementia onset or slow its progression. However, more research is needed to understand the extent of its anti-dementia properties if it will be deployed broadly in the general population. This study will examine whether lithium has anti-dementia properties in older adults who have mild cognitive impairment and are at risk of becoming demented.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 83 (actual)
- First submitted
- 24 Apr 2017
- Start date
- 2 Feb 2018
- Primary completion date
- 6 Aug 2024
- Lead sponsor
- Ariel Gildengers, MD
- Diseases
- Frontotemporal dementia, Alzheimer disease
- NCT number
- NCT03185208
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 83
- From 2 Feb 2018 to the primary completion date, 6 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Major psychiatric illness (mild psychiatric illness may be included)
- Major neurologic illness (e.g., multiple sclerosis)
- Contraindication to lithium (e.g., renal insufficiency)
- Unable to complete neuropsychological testing due to non-remediable impairment (e.g., blindness)
Who the study is looking for
- 60 years or older
- Diagnosis of Mild Cognitive Impairment
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pittsburgh Medical Center Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
Related publications
- Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial.JAMA Neurol · 2026 · PMID 41770546
This page is information, not medical advice. Discuss any trial with your doctor.